Display options
Cite
Bienvenu B, Cozon G, Hoarau C, et al. Does the route of immunoglobin replacement therapy impact quality of life and satisfaction in patients with primary immunodeficiency? Insights from the French cohort "Visages". Orphanet J Rare Dis. 2016;11(1):83doi: 10.1186/s13023-016-0452-9.
Bienvenu, B., Cozon, G., Hoarau, C., Pasquet, M., Cherin, P., Clerson, P., Hachulla, E., Crave, J. C., Delain, J. C., & Jaussaud, R. (2016). Does the route of immunoglobin replacement therapy impact quality of life and satisfaction in patients with primary immunodeficiency? Insights from the French cohort "Visages". Orphanet journal of rare diseases, 11(1), 83. https://doi.org/10.1186/s13023-016-0452-9
Bienvenu, B, et al. "Does the route of immunoglobin replacement therapy impact quality of life and satisfaction in patients with primary immunodeficiency? Insights from the French cohort "Visages"." Orphanet journal of rare diseases vol. 11,1 (2016): 83. doi: https://doi.org/10.1186/s13023-016-0452-9
Bienvenu B, Cozon G, Hoarau C, Pasquet M, Cherin P, Clerson P, Hachulla E, Crave JC, Delain JC, Jaussaud R. Does the route of immunoglobin replacement therapy impact quality of life and satisfaction in patients with primary immunodeficiency? Insights from the French cohort "Visages". Orphanet J Rare Dis. 2016 Jun 22;11(1):83. doi: 10.1186/s13023-016-0452-9. PMID: 27334100; PMCID: PMC4917986.
Copy Download .nbib Format: NLM
Share it on

Orphanet J Rare Dis. 2016 Jun 22;11(1):83. doi: 10.1186/s13023-016-0452-9.

Does the route of immunoglobin replacement therapy impact quality of life and satisfaction in patients with primary immunodeficiency? Insights from the French cohort "Visages".

Orphanet journal of rare diseases

B Bienvenu, G Cozon, C Hoarau, M Pasquet, P Cherin, P Clerson, E Hachulla, J C Crave, J C Delain, R Jaussaud

Affiliations

  1. Internal Medicine Department, University Hospital Centre of Caen, avenue de la Côte de Nacre, BP 95182, 14033, Caen cedex 9, France. [email protected].
  2. Edouard Herriot Hospital, Clinical Immunology, 5 place d'Arsonval, 69437, Lyon cedex 03, France.
  3. Renal Transplantation & Clinical immunology Department, University Hospital Centre of Tours, 2 bd Tonnellé, 37044, Tours cedex, France.
  4. Pediatric Hematology and Oncology Department, University Hospital Centre of Toulouse, 330 avenue de la Grande Bretagne, 31059, Toulouse cedex 9, France.
  5. Internal Medicine Department, Saint Antoine Hospital, 184 rue du Faubourg Saint Antoine, 75571, Paris cedex 12, France.
  6. Soladis Clinical Studies, 84 boulevard du Général Leclerc, 59100, Roubaix, France.
  7. Internal medecine Department, CHRU Lille - Hôpital Claude Huriez, 2 avenue Oscar Lambret, 59037, Lille Cedex, France.
  8. Octapharma France, 62bis avenue André Morizet, 92100, Boulogne-Billancourt, France.
  9. Internal Medicine and Infectious Diseases Department, University Hospital Centre of Reims, avenue du Gal Koenig, 51092, Reims cedex, France.

PMID: 27334100 PMCID: PMC4917986 DOI: 10.1186/s13023-016-0452-9

Abstract

BACKGROUND: IgG replacement therapy (IgRT) in primary immunodeficiencies (PID) is a lifelong treatment which may be administered intravenously (IVIg) or subcutaneously (SCIg), at hospital or at home. The objective of the VISAGE study was to investigate if route and/or place for IgRT impact patients' satisfaction regarding IgRT and quality of life (QoL) in real-life conditions.

METHODS: The study enrolled PID patients at least 15 years old receiving IgRT for at least 3 months. Satisfaction and QoL were evaluated at enrollment and over a 12-month follow-up period by Life Quality Index (LQI) which measures 3 dimensions of satisfaction: treatment interference, therapy related problems and therapy settings (factors I, II and III) and SF-36 v2 questionnaire.

RESULTS: The study included 116 PID patients (mean age 42 ± 18 years, 44 % males, 58 % with scholar or professional occupation) receiving IgRT for a mean of 8.5 ± 8.4 years. At enrollment they were receiving either home-based SCIg (51 %), hospital-based IVIg (40 %) or home-based IVIg (9 %). Patients exhibited a high degree of satisfaction regarding IgRT whatever the route and place for administration. LQI factor I was higher for home-based SCIg (86 ± 2) than for hospital-based IVIg (81 ± 3) and home-based IVIg (73 ± 5; p = 0.02 versus home-based SCIg); no difference was found for LQI factor II; LQI factor III was higher for home-based SCIg (92 ± 2) than for hospital-based IVIg (87 ± 5) and hospital-based IVIg (82 ± 3; p = 0.005 versus home-based SCIg). By contrast, every dimension of QoL was impaired. Over the follow-up period, 10 patients switched from hospital-based IVIg to home-based SCIg and improved LQI factor I (p = 0.004) and factor III (p = 0.02), while no change was noticed in LQI factors II and QoL. Meanwhile, no change in satisfaction or QoL was found in patients with stable route of IgRT. When asked on their preferred place of treatment all but one patient with home-based treatment would choose to be treated at home and 29 % of patients treated at hospital would prefer home-based IgRT.

CONCLUSION: PID patients expressed a high degree of satisfaction regarding IgRT, contrasting with impaired QoL. In real-life conditions awareness of patient's expectations regarding the route or place of IgRT may be associated with further improvement of satisfaction.

Keywords: Cohort study; Immunoglobulins; Immunotherapy; Preference; Primary immunodeficiency; Quality of life; Replacement; Satisfaction

References

  1. Ther Clin Risk Manag. 2010 Feb 02;6:1-10 - PubMed
  2. Clin Immunol. 2008 Jan;126(1):81-8 - PubMed
  3. Acta Paediatr. 2007 Oct;96(10):1474-8 - PubMed
  4. Allergy Asthma Clin Immunol. 2015 Sep 29;11:27 - PubMed
  5. Ann Allergy Asthma Immunol. 2004 Aug;93(2):160-5 - PubMed
  6. Clin Infect Dis. 2014 Nov 15;59(10):1462-70 - PubMed
  7. J Clin Immunol. 2009 Jul;29(4):501-7 - PubMed
  8. Ann Allergy Asthma Immunol. 2004 Dec;93(6):557-61 - PubMed
  9. Pediatrics. 1996 Dec;98(6 Pt 1):1127-31 - PubMed
  10. J Pediatr Health Care. 2002 Jan-Feb;16(1):16-21 - PubMed
  11. Qual Life Res. 2005 Sep;14(7):1683-91 - PubMed
  12. J Intern Med. 1991 Jan;229(1):73-7 - PubMed
  13. Asian Pac J Allergy Immunol. 2010 Jun-Sep;28(2-3):141-6 - PubMed
  14. Curr Opin Allergy Clin Immunol. 2006 Dec;6(6):434-42 - PubMed
  15. N Engl J Med. 1991 Jul 11;325(2):110-7 - PubMed
  16. Neonatal Netw. 1999 Feb;18(1):13-22 - PubMed
  17. J Clin Immunol. 2006 Jan;26(1):65-72 - PubMed
  18. Clin Drug Investig. 2015 Mar;35(3):179-85 - PubMed
  19. Front Immunol. 2014 Nov 26;5:605 - PubMed
  20. Ann Rheum Dis. 2002 Mar;61(3):277-8 - PubMed
  21. J Allergy Clin Immunol. 2004 Oct;114(4):936-42 - PubMed
  22. Expert Rev Clin Immunol. 2014 Oct;10(10):1293-307 - PubMed
  23. Ther Clin Risk Manag. 2012;8:157-67 - PubMed
  24. J Clin Immunol. 2000 Mar;20(2):94-100 - PubMed
  25. Eur J Med Res. 2010 Jun 28;15(6):238-45 - PubMed
  26. J Adv Nurs. 1995 May;21(5):917-27 - PubMed
  27. Iran J Allergy Asthma Immunol. 2006 Mar;5(1):23-7 - PubMed
  28. Am J Manag Care. 1997 Apr;3(4):579-94 - PubMed
  29. Clin Exp Immunol. 2009 Sep;157 Suppl 1:3-11 - PubMed
  30. J Clin Immunol. 2006 Mar;26(2):177-85 - PubMed
  31. Drugs. 2013 Aug;73(12):1307-19 - PubMed
  32. Patient Prefer Adherence. 2014 Mar 17;8:323-30 - PubMed
  33. Lancet. 1991 Jul 20;338(8760):162-6 - PubMed
  34. Immunodeficiency. 1993;4(1-4):81-4 - PubMed
  35. Patient Prefer Adherence. 2014 May 02;8:621-9 - PubMed
  36. Med Klin (Munich). 2008 Sep 15;103(9):620-7 - PubMed
  37. Clin Exp Immunol. 2009 Dec;158 Suppl 1:51-9 - PubMed
  38. Lancet. 1995 Feb 11;345(8946):365-9 - PubMed
  39. J Clin Immunol. 1994 Mar;14(2):90-7 - PubMed

Substances

MeSH terms

Publication Types